Scientific Publication References | Meso Scale Discovery

Results 1 - 100 of 217 for References

1
2
3
Next
Last

References	Journal	Year
A phase 1 study of prophylactic anakinra to mitigate ICANS in patients with large B-cell lymphoma Paolo Strati, Andrew Jallouk, Qing Deng, Xubin Li, Lei Feng, Ryan Sun, Sherry Adkins, Swapna Johncy, Taylor Cain, Raphael E. Steiner, Sairah Ahmed, Dai Chihara, Luis E. Fayad, Swaminathan P. Iyer, Sandra Horowitz, Loretta J. Nastoupil, Ranjit Nair, Ahmed Hassan, Taher E. Daoud, Misha Hawkins, Maria A. Rodriguez, Elizabeth J. Shpall, Jeremy L. Ramdial, Partow Kebriaei, David S. Hong, Jason R. Westin, Sattva S. Neelapu, Michael R. Green	Blood Advances	2023	View
Twenty-eight day repeated exposure of human 3D bronchial epithelial model to heated tobacco aerosols indicates decreased toxicological responses compared to cigarette smoke Fiona Chapman, Sarah Jean Pour, Roman Wieczorek, Edgar Trelles Sticken, Jessica Budde, Karin Röwer, Sandra Otte, Elizabeth Mason, Lukasz Czekala, Thomas Nahde, Grant O’Connell, Liam Simms and Matthew Stevenson	Frontiers in Toxicology	2023	View
Prostate-Specific Antigen and Female Breast Cancer-Revisited Ziyad Khatab, Ioannis Prassas, Martin Stengelin, Eleftherios P Diamandis	The Journal of Applied Laboratory Medicine	2023	View
Soluble PD-L1 as a Predictor of the Response to EGFR-TKIs in Non-small Cell Lung Cancer Patients With EGFR Mutations Yijun Jia, Xuefei Li, Chao Zhao, Shengxiang Ren, Chunxia Su, Guanghui Gao, Wei Li, Fei Zhou, Jiayu Li, and Caicun Zhou	Frontiers in Oncology	2020	View
Plasma-Derived Inflammatory Proteins Predict Oral Squamous Cell Carcinoma Kelly Yi Ping Liu, Xian Jun David Lu, Yuqi Sarah Zhu, Nhu Le, Hugh Kim, and Catherine F. Poh	Frontiers in Oncology	2018	View
A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo S Hipp, Y-T Tai, D Blanset, P Deegen, J Wahl, O Thomas, B Rattel, P J Adam, K C Anderson and M Friedrich	Leukemia	2017	View
Kinetics and Biomarkers of Severe Cytokine Release Syndrome after CD19 Chimeric Antigen Receptor-modified T Cell Therapy. Kevin A Hay, Laïla-Aïcha Hanafi, Daniel Li, Juliane Gust, W Conrad Liles, Mark M Wurfel, Jose A Lopez, Junmei Chen, Dominic Chung, Susanna Harju-Baker, Sindhu Cherian, Xueyan Chen, Stanley R Riddell, David G Maloney, Cameron J Turtle	Blood	2017	View
Serum complexed and free prostate specific antigen levels are lower in female elite athletes in comparison to control women Emma Eklund, Eleftherios P Diamandis, Carla Muytjens, Sarah Wheeler, Anu Mathew, Martin Stengelin, Eli Glezer, Galina Nikolenko, Marshall D. Brown, Yingye Zheng, Angelica Lindén Hirschberg	F1000 Research	2017	View
Time-of-Day Dictates Transcriptional Inflammatory Responses to Cytotoxic Chemotherapy. Borniger JC, Walker II WH, Gaudier-Diaz MM, et al.	Sci Rep.	2017	View
A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling. McArthur HL, Diab A, Page DB, Yuan J, Solomon SB, Sacchini V, Comstock C, Durack JC, Maybody M, Sung J, Ginsberg A, Wong P, Barlas A, Dong Z, Zhao C, Blum B, Patil S, Neville D, Comen EA, Morris EA, Kotin A, Brogi E, Wen YH, Morrow M, Lacouture ME, Sharma P, Allison JP, Hudis CA, Wolchok JD, Norton L.	Clin Cancer Res.	2016	View
Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib Plus Ipilimumab. D'Angelo SP, Shoushtari AN, Keohan ML, Dickson MA, Gounder MM, Chi P, Loo JK, Gaffney L, Schneider L, Patel Z, Erinjeri JP, Bluth M, Sjoberg A, Streicher H, Takebe N, Qin LX, Antonescu CR, DeMatteo RP, Carvajal RD, Tap WD.	Clin Cancer Res.	2016	View
Parallel profiles of inflammatory and effector memory T cells in visceral fat and liver of obesity-associated cancer patients. Conroy MJ, Galvin KC, Doyle SL, Kavanagh ME, Mongan AM, Cannon A, Moore GY, Reynolds JV, Lysaght J.	Inflammation	2016	View
Preoperative systemic levels of VEGFA, IL‐7, IL‐17A, and TNF‐β delineate two distinct groups of children with brain tumors. Sandén E, Enríquez Pérez J, Visse E, Kool M, Carén H, Siesjö P, Darabi A.	Pediatr Blood Cancer.	2016	View
CCR1 antagonism attenuates T cell trafficking to omentum and liver in obesity-associated cancer. Conroy MJ, Galvin KC, Kavanagh ME, Mongan AM, Doyle SL, Gilmartin N, O'Farrelly C, Reynolds JV, Lysaght J.	Immunol Cell Biol.	2016	View
CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice. Chen Y, Ramjiawan RR, Reiberger T, Ng MR, Hato T, Huang Y, Ochiai H, Kitahara S, Unan EC, Reddy TP, Fan C, Huang P, Bardeesy N, Zhu AX, Jain RK, Duda DG.	Hepatology	2015	View
Overexpression of the microRNA miR-433 promotes resistance to paclitaxel through the induction of cellular senescence in ovarian cancer cells. Weiner-Gorzel K, Dempsey E, Milewska M, McGoldrick A, Toh V, Walsh A, Lindsay S, Gubbins L, Cannon A, Sharpe D, O'Sullivan J, Murphy M, Madden SF, Kell M, McCann A, Furlong F.	Cancer Med.	2015	View
Radiation and SN38 treatments modulate the expression of microRNAs, cytokines and chemokines in colon cancer cells in a p53-directed manner. Pathak S, Meng WJ, Nandy SK, Ping J, Bisgin A, Helmfors L, Waldmann P, Sun XF.	Oncotarget	2015	View
Tissue-Specific Progenitor and Stem Cells Pre-Exposure of Human Adipose Mesenchymal Stem Cells to Soluble Factors Enhances Their Homing to Brain Cancer. Smith CL, Chaichana KL, Lee YM, Lin B, Stanko KM, O'Donnell T, Gupta S, Shah SR, Wang J, Wijesekera O, Delannoy M, Levchenko A, Quiñones-Hinojosa A.	Stem Cells Transl Med.	2015	View
Development of a Rapid Streptavidin Capture-Based Assay for the Tyrosine Phosphorylated CSF-1R in Peripheral Blood Mononuclear Cells. Chaturvedi S, Dell E, Siegel D, Brittingham G, Seetharam S.	Int J Biol Sci.	2013	View
Development of a robust flow cytometry-based pharmacodynamic assay to detect phospho-protein signals for phosphatidylinositol 3-kinase inhibitors in multiple myeloma. Li C, Takahashi C, Zhang L, Huseni M, Stankovich B, Mashhedi H, Lee J, French D, Anderson JE, Kim D, Howell K, Brauer MJ, Kowanetz M, Yan Y, Humke E, Ebens A, Hampton G, Lackner MR, Hegde P, Jia S.	J Transl Med	2013	View
A human tRNA methyltransferase 9-like protein prevents tumour growth by regulating LIN9 and HIF1-α. Begley U, Sosa MS, Avivar-Valderas A, Patil A, Endres L, Estrada Y, Chan CT, Su D, Dedon PC, Aguirre-Ghiso JA, Begley T.	EMBO Mol Med	2013	View
A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. Voorhees PM, Manges RF, Sonneveld P, Jagannath S, Somlo G, Krishnan A, Lentzsch S, Frank RC, Zweegman S, Wijermans PW, Orlowski RZ, Kranenburg B, Hall B, Casneuf T, Qin X, van de Velde H, Xie H, Thomas SK.	Br J Haematol	2013	View
A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2 in patients with advanced hepatocellular cancer. Zhu AX, Finn RS, Mulcahy M, Gurtler J, Sun W, Schwartz JD, Dalal RP, Joshi A, Hozak RR, Xu Y, Ancukiewicz M, Jain RK, Nugent F, Duda DG, Stuart K.	Clin Cancer Res.	2013	View
A phase I/II study of ofatumumab (GSK1841157) in Japanese and Korean patients with relapsed or refractory B-cell chronic lymphocytic leukemia. Ogawa Y, Ogura M, Suzuki T, Ando K, Uchida T, Shirasugi Y, Tobinai K, Lee JH, Kase M, Katsura K, Hotta T.	Int J Hematol.	2013	View
A randomized, placebo-controlled study of the pharmacokinetics, pharmacodynamics, and tolerability of the oral JAK2 inhibitor fedratinib (SAR302503) in healthy volunteers. Zhang M, Xu CR, Shamiyeh E, Liu F, Yin J, von Moltke LL, Smith WB.	J Clin Pharmacol.	2013	View
Abdominal obesity, independent from caloric intake, accounts for the development of intestinal tumors in Apc1638N/+ female mice. Huffman DM, Augenlicht LH, Zhang X, Lofrese JJ, Atzmon G, Chamberland JP, Mantzoros CS.	Cancer Prev Res	2013	View
Associations of interleukin-6 with vegetative but not affective depressive symptoms in terminally ill cancer patients. Inagaki M, Akechi T, Okuyama T, Sugawara Y, Kinoshita H, Shima Y, Terao K, Mitsunaga S, Ochiai A, Uchitomi Y.	Support Care Cancer	2013	View
Blood CD33(+)HLA-DR(-) myeloid-derived suppressor cells are increased with age and a history of cancer. Verschoor CP, Johnstone J, Millar J, Dorrington MG, Habibagahi M, Lelic A, Loeb M, Bramson JL, Bowdish DM.	J Leukoc Biol	2013	View
Correlation between cytokine levels and changes in fatigue and quality of life in patients with acute myeloid leukemia. Fung FY, Li M, Breunis H, Timilshina N, Minden MD, Alibhai SM.	Leuk Res.	2013	View
C-reactive protein predicts fatigue independently of depression in breast cancer patients prior to chemotherapy. Pertl MM, Hevey D, Boyle NT, Hughes MM, Collier S, O'Dwyer AM, Harkin A, John Kennedy M, Connor TJ.	Brain Behav Immun.	2013	View
Crosstalk between colon cancer cells and macrophages via inflammatory mediators and CD47 promotes tumour cell migration. Zhang Y, Sime W, Juhas M, Sjolander A.	Eur J Cancer	2013	View
CSF1 is a novel p53 target gene whose protein product functions in a feed-forward manner to suppress apoptosis and enhance p53-mediated growth arrest. Azzam G, Wang X, Bell D, Murphy ME.	PLoS One.	2013	View
Depression, cytokines, and pancreatic cancer. Breitbart W, Rosenfeld B, Tobias K, Pessin H, Ku GY, Yuan J, Wolchok J.	Psychooncology.	2013	View
Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo. Renshaw J, Taylor KR, Bishop R, Valenti M, De Haven Brandon A, Gowan S, Eccles SA, Ruddle R, Johnson LD, Raynaud FI, Selfe J, Thway K, Pietsch T, Pearson AD, Shipley J.	Clin Cancer Res.	2013	View
Elevated insulin-like growth factor binding protein-1 (IGFBP-1) in men with metastatic prostate cancer starting androgen deprivation therapy (ADT) is associated with shorter time to castration resistance and overall survival. Sharma J, Gray KP, Evan C, Nakabayashi M, Fichorova R, Rider J, Mucci L, Kantoff PW, Sweeney CJ.	Prostate.	2013	View
Endurance training in prostate cancer patients treated with androgen deprivation therapy. Hvid T, Winding K, Rinnov A, Dejgaard T, Thomsen C, Iversen P, Brasso K, Mikines KJ, van Hall G, Lindegaard B, Solomon TP, Pedersen BK.	Endocr Relat Cancer	2013	View
Evaluation of the stability, bioavailability, and hypersensitivity of the omega-3 derived anti-leukemic prostaglandin: δ(12)-prostaglandin j3. Kudva AK, Kaushal N, Mohinta S, Kennett MJ, August A, Paulson RF, Prabhu KS.	PLoS One	2013	View
Inhibition of tumor growth and metastasis in non-small cell lung cancer by LY2801653, an inhibitor of several oncokinases, including MET. Wu W, Bi C, Credille KM, Manro JR, Peek VL, Donoho GP, Yan L, Wijsman JA, Yan SB, Walgren RA.	Clin Cancer Res.	2013	View
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Das Thakur M, Salangsang F, Landman AS, Sellers WR, Pryer NK, Levesque MP, Dummer R, McMahon M, Stuart DD.	Nature. 2013 Feb 14;494(7436):251-5.	2013	View
Phase I study of Ofatumumab, a human anti-CD20 antibody, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. Ogura M, Hatake K, Tobinai K, Uchida T, Suzuki T, Terui Y, Yokoyama M, Maruyama D, Mori M, Jewell RC, Katsura K, Hotta T.	Jpn J Clin Oncol	2013	View
Phase I study of Dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma. Angevin E, Lopez-Martin JA, Lin CC, Gschwend JE, Harzstark A, Castellano D, Soria JC, Sen P, Chang J, Shi M, Kay A, Escudier B.	Clin Cancer Res	2013	View
Phase II study evaluating 2 dosing schedules of oral Foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. Shah MA, Wainberg ZA, Catenacci DVT, Hochster HS, Ford J, Kunz P, Lee F, Kallender H, Cecchi F, Rabe DC, Keer H, Martin A, Liu Y, Gagnon R, Bonate P, Liu L, Gilmer T, Bottaro DP.	PLoS One	2013	View
Preclinical Evaluation of the Toxicological Effects of a Novel Constrained Ethyl Modified Antisense Compound Targeting Signal Transducer and Activator of Transcription 3 in Mice and Cynomolgus Monkeys. Burel SA, Han SR, Lee HS, Norris DA, Lee BS, Machemer T, Park SY, Zhou T, He G, Kim Y, MacLeod AR, Monia BP, Lio S, Kim TW, Henry SP.	Nucleic Acid Ther.	2013	View
Puerperal mastitis: a reproductive event of importance affecting anti-mucin antibody levels and ovarian cancer risk. Cramer DW, Williams K, Vitonis AF, Yamamoto HS, Stuebe A, Welch WR, Titus L, Fichorova RN.	Cancer Causes Control.	2013	View
RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation. Holderfield M, Merritt H, Chan J, Wallroth M, Tandeske L, Zhai H, Tellew J, Hardy S, Hekmat-Nejad M, Stuart DD, McCormick F, Nagel TE.	Cancer Cell	2013	View
S49076 is a novel kinase inhibitor of MET, AXL and FGFR with strong preclinical activity alone and in association with bevacizumab. Burbridge MF, Bossard CJ, Saunier C, Fejes I, Bruno A, Leonce S, Ferry G, Da Violante G, Bouzom F, Cattan V, Jacquet-Bescond A, Comoglio PM, Lockhart BP, Boutin JA, Cordi A, Ortuno JC, Pierre A, Hickman JA, Cruzalegui FH, Depil S.	Mol Cancer Ther.	2013	View
Serum folate receptor alpha, mesothelin and megakaryocyte potentiating factor in ovarian cancer: association to disease stage and grade and comparison to CA125 and HE4. O'Shannessy DJ, Somers EB, Palmer LM, Thiel RP, Oberoi P, Heath R, Marcucci L.	J Ovarian Res	2013	View
Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer. Mitsunaga S, Ikeda M, Shimizu S, Ohno I, Furuse J, Inagaki M, Higashi S, Kato H, Terao K, Ochiai A.	Br J Cancer	2013	View
Shedding LIGHT (TNFSF14) on the tumor microenvironment of colorectal cancer liver metastases. Qin JZ, Upadhyay V, Prabhakar B, Maker AV.	J Transl Med	2013	View
Suppression of DHT-induced paracrine stimulation of endothelial cell growth by estrogens via prostate cancer cells. Wen J, Zhao Y, Li J, Weng C, Cai J, Yang K, Yuan H, Imperato-McGinley J, Zhu YS.	Prostate	2013	View
Targeting IGF-IR with ganitumab inhibits tumorigenesis and increases durability of response to androgen-deprivation therapy in VCaP prostate cancer xenografts. Fahrenholtz CD, Beltran PJ, Burnstein KL.	Mol Cancer Ther	2013	View
Tetrathiomolybdate-associated copper depletion decreases circulating endothelial progenitor cells in women with breast cancer at high risk of relapse. Jain S, Cohen J, Ward MM, Kornhauser N, Chuang E, Cigler T, Moore A, Donovan D, Lam C, Cobham MV, Schneider S, Hurtado Rúa SM, Benkert S, Mathijsen Greenwood C, Zelkowitz R, Warren JD, Lane ME, Mittal V, Rafii S, Vahdat LT.	Ann Oncol	2013	View
The histone deacetylase inhibitor UCL67022 has potent activity in multiple myeloma and non-Hodgkin lymphoma pre-clinical models. Maharaj L, Marson CM, Middleton BJ, Rioja AS, Perry J, Oakervee H, Cavenagh J, Joel SP, Popat R.	Br J Haematol.	2013	View
Vascular endothelial growth factor-D-mediated blockade of regulatory T cells within tumors is induced by hematopoietic stem cell transplantation. Udagawa T, Narumi K, Suzuki K, Aida K, Miyakawa R, Ikarashi Y, Makimoto A, Chikaraishi T, Yoshida T, Aoki K.	J Immunol.	2013	View
A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer. Hudes G, Tagawa ST, Whang YE, Qi M, Qin X, Puchalski TA, Reddy M, Cornfeld M, Eisenberger M.	Invest New Drugs.	2012	View
A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors. Banerji U, van Doorn L, Papadatos-Pastos D, Kristeleit R, Debnam P, Tall M, Stewart A, Raynaud F, Garrett MD, Toal M, Hooftman L, De Bono JS, Verweij J, Eskens FA.	Clin Cancer Res.	2012	View
A Phase I Study of the Combination of Sorafenib With Temozolomide and Radiation Therapy for the Treatment of Primary and Recurrent High-Grade Gliomas. Den RB, Kamrava M, Sheng Z, Werner-Wasik M, Dougherty E, Marinucchi M, Lawrence YR, Hegarty S, Hyslop T, Andrews DW, Glass J, Friedman DP, Green MR, Camphausen K, Dicker AP.	Int J Radiat Oncol Biol Phys.	2012	View
A Potent Anti-HB-EGF Monoclonal Antibody Inhibits Cancer Cell Proliferation and Multiple Angiogenic Activities of HB-EGF. Sato S, Drake AW, Tsuji I, Fan J.	PLoS One	2012	View
Analytical approach to characterize the intratumoral pharmacokinetics and pharmacodynamics of gefitinib in a glioblastoma model. Sharma J, Lv H, Gallo JM.	J Pharm Sci.	2012	View
AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity. Yap TA, Walton MI, Grimshaw KM, Te Poele RH, Eve PD, Valenti MR, de Haven BAK, Martins V, Zetterlund A, Heaton SP, Heinzmann K, Jones PS, Feltell RE, Reule M, Woodhead SJ, Davies TG, Lyons JF, Raynaud FI, Eccles SA, Workman P, Thompson NT, Garrett MD.	Clin Cancer Res.	2012	View
BAY 1000394, a novel cyclin-dependent kinase inhibitor, with potent antitumor activity in mono- and in combination treatment upon oral application. Siemeister G, Lucking U, Wengner AM, Lienau P, Steinke W, Schatz C, Mumberg D, Ziegelbauer K.	Mol Cancer Ther.	2012	View
Biomarkers of response to Akt inhibitor MK-2206 in breast cancer. Sangai T, Akcakanat A, Chen H, Tarco E, Wu Y, Do KA, Miller TW, Arteaga CL, Mills GB, Gonzalez-Angulo AM, Meric-Bernstam F.	Clin Cancer Res.	2012	View
Comparison of Subcutaneous and Intravenous Administration of Trastuzumab: A Phase I/Ib Trial in Healthy Male Volunteers and Patients With HER2-Positive Breast Cancer. Wynne C, Harvey V, Schwabe C, Waaka D, McIntyre C, Bittner B.	J Clin Pharmacol.	2012	View
Dependence of Wilms tumor cells on signaling through insulin-like growth factor 1 in an orthotopic xenograft model targetable by specific receptor inhibition. Bielen A, Box G, Perryman L, Bjerke L, Popov S, Jamin Y, Jury A, Valenti M, Brandon Ade H, Martins V, Romanet V, Jeay S, Raynaud FI, Hofmann F, Robinson SP, Eccles SA, Jones C.	Proc Natl Acad Sci U S A.	2012	View
Effects of Sorafenib on Intra-Tumoral Interstitial Fluid Pressure and Circulating Biomarkers in Patients with Refractory Sarcomas (NCI Protocol 6948). Raut CP, Boucher Y, Duda DG, Morgan JA, Quek R, Ancukiewicz M, Lahdenranta J, Eder JP, Demetri GD, Jain RK.	PLoS One.	2012	View
Enhanced apoptosis and tumor growth suppression elicited by combination of MEK and mTOR kinase inhibitors. Holt SV, Logie A, Davies BR, Alferez D, Runswick S, Fenton S, Chresta CM, Gu Y, Zhang J, Wu YL, Wilkinson RW, Guichard S, Smith PD.	Cancer Res.	2012	View
High-anxious individuals show increased chronic stress burden, decreased protective immunity, and increased cancer progression in a mouse model of squamous cell carcinoma. Dhabhar FS, Saul AN, Holmes TH, Daugherty C, Neri E, Tillie JM, Kusewitt D, Oberyszyn TM.	PLoS One.	2012	View
Immuno-PET of the hepatocyte growth factor receptor Met using the 1-armed antibody Onartuzumab. Jagoda EM, Lang L, Bhadrasetty V, Histed S, Williams M, Kramer-Marek G, Mena E, Rosenblum L, Marik J, Tinianow JN, Merchant M, Szajek L, Paik C, Cecchi F, Raffensperger K, Jose-Dizon JM, Bottaro DP, Choyke P.	J Nucl Med.	2012	View
Impaired pten expression in human malignant peripheral nerve sheath tumours. Bradtmöller M, Hartmann C, Zietsch J, Jäschke S, Mautner VF, Kurtz A, Park SJ, Baier M, Harder A, Reuss D, von Deimling A, Heppner FL, Holtkamp N.	PLoS One	2012	View
Interrelationship of depression, stress and inflammation in cancer patients: A preliminary study. Archer JA, Hutchison IL, Dorudi S, Stansfeld SA, Korszun A.	J Affect Disord.	2012	View
Langerhans cells from human cutaneous squamous cell carcinoma induce strong type 1 immunity. Fujita H, Suárez-Fariñas M, Mitsui H, Gonzalez J, Bluth MJ, Zhang S, Felsen D, Krueger JG, Carucci JA.	J Invest Dermatol.	2012	View
Mechanism of anti-glioma activity and in vivo efficacy of the cannabinoid ligand KM-233. Gurley SN, Abidi AH, Allison P, Guan P, Duntsch C, Robertson JH, Kosanke SD, Keir ST, Bigner DD, Elberger AJ, Moore BM 2nd.	J Neurooncol.	2012	View
Monocytes and γδ T cells control the acute phase response to intravenous zoledronate: Insights from a phase IV safety trial. Welton JL, Morgan MP, Martí S, Stone MD, Moser B, Sewell AK, Turton J, Eberl M.	J Bone Miner Res.	2012	View
mTOR kinase inhibitor potentiates apoptosis of PI3K and MEK inhibitors in diagnostically defined subpopulations. Vijapurkar U, Robillard L, Zhou S, Degtyarev M, Lin K, Truong T, Tremayne J, Ross LB, Pei Z, Friedman LS, Blackwood EM, Belvin M.	Cancer Lett.	2012	View
Pharmacokinetic and pharmacodynamic analysis of circulating biomarkers of anti-NRP1, a novel anti-angiogenesis agent, in two phase I trials in patients with advanced solid tumors. Xin Y, Li J, Wu J, Kinard R, Weekes CD, Patnaik A, Lorusso PM, Brachmann R, Tong RK, Yan Y, Watts R, Bai S, Hegde PS.	Clin Cancer Res.	2012	View
Pharmacokinetic and pharmacodynamic comparability study of moxetumomab pasudotox, an immunotoxin targeting CD22, in cynomolgus monkeys. Wang B, Liang M, Yao Z, Vainshtein I, Lee R, Schneider A, Zusmanovich M, Jin F, O'Connor K, Donato-Weinstein B, Iciek L, Lavallee T, Roskos L.	J Pharm Sci.	2012	View
Pharmacokinetics and Pharmacodynamics of Figitumumab, a Monoclonal Antibody Targeting the Insulin-Like Growth Factor 1 Receptor, in Healthy Participants. Yin D, Sleight B, Alvey C, Hansson AG, Bello A.	J Clin Pharmacol.	2012	View
Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors. Annunziata CM, Kohn EC, Lorusso P, Houston ND, Coleman RL, Buzoianu M, Robbie G, Lechleider R.	Invest New Drugs.	2012	View
Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors. Murakami H, Doi T, Yamamoto N, Watanabe J, Boku N, Fuse N, Yoshino T, Ohtsu A, Otani S, Shibayama K, Takubo T, Loh E.	Cancer Chemother Pharmacol.	2012	View
Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer. De Boer RH, Kotasek D, White S, Koczwara B, Mainwaring P, Chan A, Melara R, Ye Y, Adewoye AH, Sikorski R, Kaufman PA.	Breast Cancer Res Treat.	2012	View
Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer. Pienta KJ, Machiels JP, Schrijvers D, Alekseev B, Shkolnik M, Crabb SJ, Li S, Seetharam S, Puchalski TA, Takimoto C, Elsayed Y, Dawkins F, de Bono JS.	Invest New Drugs.	2012	View
Phase I clinical trial of mixed bacterial vaccine (Coley's toxins) in patients with NY-ESO-1 expressing cancers: Immunological effects and clinical activity. Karbach J, Neumann A, Brand K, Wahle C, Siegel E, Maeurer M, Ritter E, Tsuji T, Gnjatic S, Old LJ, Ritter G, Jäger E.	Clin Cancer Res.	2012	View
Phase I Study of Cetuximab, Irinotecan, and Vandetanib (ZD6474) as Therapy for Patients with Previously Treated Metastastic Colorectal Cancer. Meyerhardt JA, Ancukiewicz M, Abrams TA, Schrag D, Enzinger PC, Chan JA, Kulke MH, Wolpin BM, Goldstein M, Blaszkowsky L, Zhu AX, Elliott M, Regan E, Jain RK, Duda DG.	PLoS One.	2012	View
Phase II Study of Bevacizumab in Patients With HIV-Associated Kaposi's Sarcoma Receiving Antiretroviral Therapy. Uldrick TS, Wyvill KM, Kumar P, O'Mahony D, Bernstein W, Aleman K, Polizzotto MN, Steinberg SM, Pittaluga S, Marshall V, Whitby D, Little RF, Yarchoan R.	J Clin Oncol.	2012	View
PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. Meric-Bernstam F, Akcakanat A, Chen H, Do KA, Sangai T, Adkins F, Gonzalez-Angulo AM, Rashid A, Crosby K, Dong M, Phan AT, Wolff RA, Gupta S, Mills GB, Yao J.	Clin Cancer Res.	2012	View
Pre- and post-operative plasma glial fibrillary acidic protein levels in patients with newly diagnosed gliomas. Husain H, Savage W, Grossman SA, Ye X, Burger PC, Everett A, Bettegowda C, Diaz LA Jr, Blair C, Romans KE, Holdhoff M.	J Neurooncol.	2012	View
Radiosensitization by the novel DNA intercalating agent vosaroxin. Gordon IK, Graves C, Kil WJ, Meushaw T, Tofilon P, Camphausen K.	Radiat Oncol.	2012	View
Selective antagonist reveals the role of prostaglandin receptor EP2 in cancer cell proliferation, invasion and inflammation. Jiang J, Dingledine R.	J Pharmacol Exp Ther.	2012	View
Synthesis of site-specific antibody-drug conjugates using unnatural amino acids. Axup JY, Bajjuri KM, Ritland M, Hutchins BM, Kim CH, Kazane SA, Halder R, Forsyth JS, Santidrian AF, Stafin K, Lu Y, Tran H, Seller AJ, Biroc SL, Szydlik A, Pinkstaff JK, Tian F, Sinha SC, Felding-Habermann B, Smider VV, Schultz PG.	Proc Natl Acad Sci U S A.	2012	View
Targeted MET inhibition in castration-resistant prostate cancer: A randomized phase 2 study and biomarker analysis with Rilotumumab plus Mitoxantrone and Prednisone. Ryan CJ, Rosenthal M, Ng S, Alumkal J, Picus J, Gravis G, Fizazi K, Forget F, Machiels JP, Srinivas S, Zhu M, Tang R, Oliner KS, Jiang Y, Loh E, Dubey S, Gerritsen WR.	Clin Cancer Res.	2012	View
The Association of PI3 Kinase Signaling and Chemoresistance in Advanced Ovarian Cancer. Carden CP, Stewart A, Thavasu P, Kipps E, Pope L, Crespo M, Miranda S, Attard G, Garrett MD, Clarke PA, Workman P, de Bono JS, Gore M, Kaye SB, Banerji U.	Mol Cancer Ther.	2012	View
The CEA/CD3-Bispecific Antibody MEDI-565 (MT111) Binds a Nonlinear Epitope in the Full-Length but Not a Short Splice Variant of CEA. Peng L, Oberst MD, Huang J, Brohawn P, Morehouse C, Lekstrom K, Baeuerle PA, Wu H, Yao Y, Coats SR, Dall'acqua W, Damschroder M, Hammond SA.	PLoS One.	2012	View
The role of TRKA signaling in IL-10 production by apoptotic tumor cell-activated macrophages. Ley S, Weigert A, Weichand B, Henke N, Mille-Baker B, Janssen RA, Brüne B.	Oncogene.	2012	View
A phase 2 study of pegylated interferon α-2b (PEG-Intron®) in children with diffuse intrinsic pontine glioma. Warren, K., Bent, R., Wolters, P.L., Prager, A., Hanson, R., Packer, R., Shih, J., Camphausen, K.	Cancer.	2011	View
A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. Wen, P.Y., Schiff, D., Cloughesy, T.F., Raizer, J.J., Laterra, J., Smitt, M., Wolf, M., Oliner, K.S., Anderson, A., Zhu, M., Loh, E., Reardon, D.A.	Neuro Oncol.	2011	View
A Pilot Study of MUC-1/CEA/TRICOM Poxviral-Based Vaccine in Patients with Metastatic Breast and Ovarian Cancer. Mohebtash, M., Tsang, K.Y., Madan, R.A., Huen, N.Y., Poole, D.J., Jochems, C., Jones, J., Ferrara, T., Heery, C.R., Arlen, P.M., Steinberg, S.M., Pazdur, M., Rauckhorst, M., Jones, E.C., Dahut, W.L., Schlom, J., Gulley, J.L.	Clin Cancer Res.	2011	View
Anti-tumor efficacy of naked siRNAs for ERBB3 or AKT2 against lung adenocarcinoma cell xenografts. Sithanandam, G., Fornwald, L.W., Fields, J.R., Morris, N.L., Anderson, L.M.	Int J Cancer.	2011	View
Assessing the activity of cediranib, a VEGFR-2/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR family. Brave SR, Ratcliffe K, Wilson Z, James NH, Ashton S, Wainwright A, Kendrew J, Dudley P, Broadbent N, Sproat G, Taylor S, Barnes C, Silva JC, Farnsworth CL, Hennequin L, Ogilvie DJ, Jürgensmeier JM, Shibuya M, Wedge SR, Barry ST.	Mol Cancer Ther	2011	View
Autophagy-dependent regulation of the DNA damage response protein ribonucleotide reductase 1. Dyavaiah, M., Rooney, J.P., Chittur, S.V., Lin, Q., Begley, T.J.	Mol Cancer Res.	2011	View
B regulatory cells and the tumor-promoting actions of TNF-a during squamous carcinogenesis. Schioppa, T., Moore, R., Thompson, R.G., Rosser, E.C., Kulbe, H., Nedospasov, S., Mauri, C., Coussens, L.M., Balkwill, F.R.	Proc Natl Acad Sci USA.	2011	View

Results 1 - 100 of 217 for References

1
2
3
Next
Last

Please Sign In

User name

Password

References

Search References

Year

Species

Disease Focus

Products

Services

Orders & Support

Key Topics